| Year |
Citation |
Score |
| 2024 |
Winkler J, Tan W, Diadhiou CM, McGinnis CS, Abbasi A, Hasnain S, Durney S, Atamaniuc E, Superville D, Awni L, Lee JV, Hinrichs JH, Wagner PS, Singh N, Hein MY, ... ... Goga A, et al. Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes. The Journal of Clinical Investigation. 134. PMID 39225101 DOI: 10.1172/JCI164227 |
0.345 |
|
| 2024 |
Pena G, Rohrberg J, Goga A, Heald R. Changes in spindle morphology driven by TPX2 overexpression in MYC-driven breast cancer cells. Micropublication Biology. 2024. PMID 38660563 DOI: 10.17912/micropub.biology.001182 |
0.324 |
|
| 2024 |
Jacobo Jacobo M, Donnella HJ, Sobti S, Kaushik S, Goga A, Bandyopadhyay S. An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer. Scientific Reports. 14: 3694. PMID 38355954 DOI: 10.1038/s41598-024-53999-w |
0.347 |
|
| 2023 |
Navickas A, Asgharian H, Winkler J, Fish L, Garcia K, Markett D, Dodel M, Culbertson B, Miglani S, Joshi T, Yin K, Nguyen P, Zhang S, Stevers N, Hwang HW, ... ... Goga A, et al. An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus. Nature Cell Biology. PMID 37156909 DOI: 10.1038/s41556-023-01141-9 |
0.328 |
|
| 2020 |
Komoll RM, Hu Q, Olarewaju O, von Döhlen L, Yuan Q, Xie Y, Tsay HC, Daon J, Qin R, Manns MP, Sharma AD, Goga A, Ott M, Balakrishnan A. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. Journal of Hepatology. PMID 32738449 DOI: 10.1016/J.Jhep.2020.07.039 |
0.392 |
|
| 2020 |
Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch ML, Camarda R, Balakrishnan S, Shankar R, Zhou A, Chang AN, Chen B, ... ... Goga A, et al. MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. Cell Reports. 30: 3368-3382.e7. PMID 32160543 DOI: 10.1016/J.Celrep.2020.02.041 |
0.429 |
|
| 2020 |
Vidula N, Nanda R, Miller K, Pohlmann PR, Abramson VG, Emens LA, Park BH, Liu MC, Goga A, Rugo HS. Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. Journal of Clinical Oncology. 38: TPS1114-TPS1114. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps1114 |
0.385 |
|
| 2020 |
Chien AJ, Gliwa AS, Rahmaputri S, Dittrich HF, Majure MC, Rugo HS, Melisko ME, Munster PN, Park JW, Moasser MM, Matloubian M, Lea T, Rohrberg J, Krings G, Goga A. A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression. Journal of Clinical Oncology. 38: 1076-1076. DOI: 10.1200/Jco.2020.38.15_Suppl.1076 |
0.317 |
|
| 2020 |
Vidula N, Nanda R, Miller K, Abramson V, Pohlmann P, Brufsky A, Park B, Liu M, Goga A, Rugo HS. Abstract OT2-04-05: Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-Ot2-04-05 |
0.36 |
|
| 2019 |
Goga A, Rohrberg J, Corella A, Taileb M, Kilinc S, Jokisch M, Camarda R, Zhou A, Balakrishnan S, Chang A, Klein-Connolly H. Abstract P3-09-01: MYC dysregulates mitotic spindle function in triple-negative breast cancer creating a dependency on TPX2 Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-09-01 |
0.459 |
|
| 2019 |
Vidula N, Goga A, Hwang J, Liu M, Park B, Nanda R, Pohlmann P, Storniolo A, Brufsky A, Abramson V, Rugo H. Abstract OT3-04-04: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot3-04-04 |
0.403 |
|
| 2019 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Kuhn J, Dumont S, Mccormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC Cancer Research. 79: 2902-2902. DOI: 10.1158/1538-7445.Am2019-2902 |
0.373 |
|
| 2018 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, ... ... Goga A, et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nature Medicine. PMID 30478424 DOI: 10.1038/S41591-018-0264-7 |
0.31 |
|
| 2018 |
Fish L, Zhang S, Yu JX, Culbertson B, Zhou AY, Goga A, Goodarzi H. Cancer cells exploit an orphan RNA to drive metastatic progression. Nature Medicine. PMID 30397354 DOI: 10.1038/S41591-018-0230-4 |
0.415 |
|
| 2018 |
Roy S, Hooiveld GJ, Seehawer M, Caruso S, Heinzmann F, Schneider AT, Frank AK, Cardenas DV, Sonntag R, Luedde M, Trautwein C, Stein I, Pikarsky E, Loosen S, Tacke F, ... ... Goga A, et al. microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-associated Protein 1 to Suppress Hepatocarcinogenesis. Gastroenterology. PMID 30165047 DOI: 10.1053/J.Gastro.2018.08.032 |
0.371 |
|
| 2018 |
Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nature Chemical Biology. PMID 29942081 DOI: 10.1038/S41589-018-0081-9 |
0.413 |
|
| 2018 |
Nguyen QH, Pervolarakis N, Blake K, Ma D, Davis RT, James N, Phung AT, Willey E, Kumar R, Jabart E, Driver I, Rock J, Goga A, Khan SA, Lawson DA, et al. Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity. Nature Communications. 9: 2028. PMID 29795293 DOI: 10.1038/S41467-018-04334-1 |
0.371 |
|
| 2018 |
Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson VG, Rugo HS. A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. Journal of Clinical Oncology. 36: TPS1113-TPS1113. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1113 |
0.376 |
|
| 2018 |
Donnella H, Webber J, Shokat K, Goga A, Gordan J, Bandyopadhyay S. Abstract A45: Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A45 |
0.445 |
|
| 2018 |
Vidula N, Goga A, Krummel M, Hwang J, Liu M, Park B, Nanda R, Pohlmann P, Storniolo A, Poznak CV, Brufsky A, Abramson V, Wolff A, Rugo H. Abstract OT1-02-03: TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot1-02-03 |
0.384 |
|
| 2018 |
Camarda R, Williams J, Malkov S, Zimmerman LJ, Manning S, Aran D, Beardsley A, Mark DVd, Haren Jv, Chen Y, Berdan C, Louie S, Mahieu C, Winkler J, Willey E, ... ... Goga A, et al. Abstract 2398: Tumor cell-adipocyte gap junctions activate lipolysis in breast cancer Cancer Research. 78: 2398-2398. DOI: 10.1158/1538-7445.Am2018-2398 |
0.437 |
|
| 2018 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Hemmati GG, Krings G, Haringsma HJ, Simmons AD, Harding TC, Goga A, Blakely C, Bivona T, Bandyopadhyay S. Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer Cancer Research. 78: 1957-1957. DOI: 10.1158/1538-7445.Am2018-1957 |
0.36 |
|
| 2017 |
Aran D, Camarda R, Odegaard J, Paik H, Oskotsky B, Krings G, Goga A, Sirota M, Butte AJ. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nature Communications. 8: 1077. PMID 29057876 DOI: 10.1038/S41467-017-01027-Z |
0.376 |
|
| 2017 |
Shin PJ, Zhu Z, Camarda R, Bok RA, Zhou AY, Kurhanewicz J, Goga A, Vigneron DB. Cancer recurrence monitoring using hyperpolarized [1-(13)C]pyruvate metabolic imaging in murine breast cancer model. Magnetic Resonance Imaging. PMID 28716678 DOI: 10.1016/J.Mri.2017.07.014 |
0.432 |
|
| 2017 |
Camarda R, Williams J, Goga A. In vivo Reprogramming of Cancer Metabolism by MYC. Frontiers in Cell and Developmental Biology. 5: 35. PMID 28443280 DOI: 10.3389/Fcell.2017.00035 |
0.413 |
|
| 2017 |
Kessenbrock K, Smith P, Steenbeek SC, Pervolarakis N, Kumar R, Minami Y, Goga A, Hinck L, Werb Z. Diverse regulation of mammary epithelial growth and branching morphogenesis through noncanonical Wnt signaling. Proceedings of the National Academy of Sciences of the United States of America. PMID 28270600 DOI: 10.1073/Pnas.1701464114 |
0.357 |
|
| 2017 |
Anderton B, Camarda R, Balakrishnan S, Balakrishnan A, Kohnz RA, Lim L, Evason KJ, Momcilovic O, Kruttwig K, Huang Q, Xu G, Nomura DK, Goga A. MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. Embo Reports. PMID 28219903 DOI: 10.15252/Embr.201643068 |
0.701 |
|
| 2017 |
Goga A. Abstract IA17: Synthetic-lethal strategies for MYC-driven cancers Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Ia17 |
0.433 |
|
| 2016 |
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, ... ... Goga A, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine. PMID 27775705 DOI: 10.1038/Nm.4213 |
0.478 |
|
| 2016 |
Kohnz RA, Roberts LS, DeTomaso D, Bideyan L, Yan P, Bandyopadhyay S, Goga A, Yosef N, Nomura DK. Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity. Acs Chemical Biology. PMID 27380425 DOI: 10.1021/Acschembio.6B00433 |
0.412 |
|
| 2016 |
Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, Nomura DK. GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity. Cell Chemical Biology. PMID 27185638 DOI: 10.1016/J.Chembiol.2016.03.017 |
0.434 |
|
| 2016 |
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nature Medicine. PMID 26950360 DOI: 10.1038/Nm.4055 |
0.457 |
|
| 2016 |
Zhang X, Li M, Momcilovic O, Beardsley A, Camarda R, Goga A. Functional annotation of cancer driver genes in breast cancer patient-derived xenografts to identify a novel target for PARP inhibitors. Journal of Clinical Oncology. 34: e23192-e23192. DOI: 10.1200/Jco.2016.34.15_Suppl.E23192 |
0.429 |
|
| 2016 |
Majure MC, Gasol Cudós A, Angelidakis AN, Melisko ME, Karwat AR, Chien AJ, Goga A, Moasser MM, Park JW, DeLuca AN, Rugo HS. Addition of pazopanib (PZ) to endocrine therapy in hormone resistant advanced breast cancer (ABC). Journal of Clinical Oncology. 34: 560-560. DOI: 10.1200/Jco.2016.34.15_Suppl.560 |
0.304 |
|
| 2016 |
Horiuchi D, Zhou AY, Corella AN, Yau C, Balakrishnan S, Kessenbrock K, Lawson DA, Camarda R, Anderton BN, Bazarov AV, Eyob H, Rohrberg J, Yaswen P, McManus MT, Rugo HS, ... ... Goga A, et al. Abstract B34: PIM kinase as a novel therapeutic target for triple-negative breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B34 |
0.498 |
|
| 2016 |
Samson S, Zhou AY, Martins M, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan J, Levin R, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemens P, ... ... Goga A, et al. Abstract C88: Genomics, advocacy, and emerging therapeutics to address triple-negative breast cancer (TNBC) outcome disparities. Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-C88 |
0.408 |
|
| 2016 |
Goga A, Camarda R, Zhou A, Kohnz R, Balakrishnan S, Anderton B, Mahieu C, Eyob H, Krings G, Nomura D. Abstract PD3-05: Inhibition of fatty-acid oxidation as a therapy for triple-negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd3-05 |
0.437 |
|
| 2016 |
Rohrberg J, Corella A, Balakrishnan S, Goga A. Abstract 2822: TPX2 overexpression is essential for the survival of MYC-driven triple negative breast cancer Cancer Research. 76: 2822-2822. DOI: 10.1158/1538-7445.Am2016-2822 |
0.476 |
|
| 2016 |
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. Abstract 2673: Inhibition of fatty-acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer Cancer Research. 76: 2673-2673. DOI: 10.1158/1538-7445.Am2016-2673 |
0.448 |
|
| 2015 |
Caswell JL, Camarda R, Zhou AY, Huntsman S, Hu D, Brenner SE, Zaitlen N, Goga A, Ziv E. Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors. Human Molecular Genetics. PMID 26472073 DOI: 10.1093/Hmg/Ddv432 |
0.359 |
|
| 2015 |
Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, Yaswen P, Goga A, Werb Z. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. PMID 26416748 DOI: 10.1038/Nature15260 |
0.402 |
|
| 2015 |
Evason KJ, Francisco MT, Juric V, Balakrishnan S, Lopez Pazmino Mdel P, Gordan JD, Kakar S, Spitsbergen J, Goga A, Stainier DY. Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish. Plos Genetics. 11: e1005305. PMID 26134322 DOI: 10.1371/Journal.Pgen.1005305 |
0.402 |
|
| 2015 |
Kohnz RA, Mulvihill MM, Chang JW, Hsu KL, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, Nomura DK. Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. Acs Chemical Biology. 10: 1624-30. PMID 25945974 DOI: 10.1021/Acschembio.5B00053 |
0.43 |
|
| 2015 |
Huskey NE, Guo T, Evason KJ, Momcilovic O, Pardo D, Creasman KJ, Judson RL, Blelloch R, Oakes SA, Hebrok M, Goga A. CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation. Stem Cell Reports. 4: 374-89. PMID 25733019 DOI: 10.1016/J.Stemcr.2015.01.019 |
0.387 |
|
| 2015 |
Cox JE, McClure LV, Goga A, Sullivan CS. Pan-viral-microRNA screening identifies interferon inhibition as a common function of diverse viruses. Proceedings of the National Academy of Sciences of the United States of America. 112: 1856-61. PMID 25624489 DOI: 10.1073/Pnas.1417891112 |
0.309 |
|
| 2015 |
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, ... ... Goga A, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discovery. 5: 154-67. PMID 25501949 DOI: 10.1158/2159-8290.Cd-14-0552 |
0.401 |
|
| 2015 |
Majure MC, Melisko ME, Karwat AR, Chien AJ, Goga A, Moasser MM, Park JW, DeLuca AN, Rugo HS. Role of pazopanib (PZ) in modulating hormone resistance in advanced breast cancer (ABC). Journal of Clinical Oncology. 33: 529-529. DOI: 10.1200/Jco.2015.33.15_Suppl.529 |
0.303 |
|
| 2015 |
Zhou AY, Martins MM, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji A, ... ... Goga A, et al. Abstract B48: Identification of novel drug interactions with MYC via a quantitative chemical-genetic interaction map Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B48 |
0.378 |
|
| 2015 |
Camarda R, Balakrishnan S, Zhou AY, Anderton B, Eyob H, Kohnz R, Nomura DK, Goga A. Abstract A03: Integrative analyses reveal distinct metabolic dysregulation in MYC-driven, basal breast cancer Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A03 |
0.461 |
|
| 2015 |
Anderton B, Balakrishnan A, Balakrishnan S, Lim L, Kohnz R, Nomura D, Goga A. Abstract A01: MYC regulates glutathione depletion and glutamine utilization via miR-18a in vivo Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A01 |
0.704 |
|
| 2015 |
Zhou AY, Martins MM, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji A, ... ... Goga A, et al. Abstract B44: A systems approach combining genomics, advocacy, and emerging novel therapeutics to address triple-negative breast cancer (TNBC) outcomes disparities Cancer Epidemiology, Biomarkers & Prevention. 24. DOI: 10.1158/1538-7755.Disp14-B44 |
0.407 |
|
| 2015 |
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji A, ... ... Goga A, et al. Abstract PR15: Functional analysis of diverse oncogenic driver mutations using an isogenic cell line library identifies novel drug responses and alterations in metabolism Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr15 |
0.426 |
|
| 2015 |
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji A, ... ... Goga A, et al. Abstract PR07: Functional analysis of diverse oncogenic driver mutations using an isogenic cell line library identifies novel drug responses and alterations in metabolism Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-Pr07 |
0.429 |
|
| 2015 |
Sarosiek KA, Karst A, Winter P, Sorrentino A, Bandyopadhyay S, Goga A, Wood KC, Drapkin R, Letai A. Abstract 970: Broad therapy resistance is induced by suppression of apoptotic priming by lineage programs and oncogenic activation Cancer Research. 75: 970-970. DOI: 10.1158/1538-7445.Am2015-970 |
0.403 |
|
| 2014 |
Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 124: 2081-90. PMID 25143484 DOI: 10.1182/Blood-2014-06-584524 |
0.419 |
|
| 2014 |
Horiuchi D, Anderton B, Goga A. Taking on challenging targets: making MYC druggable. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. e497-502. PMID 24857145 DOI: 10.14694/EdBook_AM.2014.34.e497 |
0.34 |
|
| 2014 |
Benjamin DI, Louie SM, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A, Bandyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng SW, Nomura DK. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. Acs Chemical Biology. 9: 1340-50. PMID 24738946 DOI: 10.1021/Cb5001907 |
0.429 |
|
| 2014 |
Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1472-9. PMID 24711549 DOI: 10.1200/Jco.2013.52.1161 |
0.364 |
|
| 2014 |
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, ... ... Goga A, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discovery. 4: 232-45. PMID 24356096 DOI: 10.1158/2159-8290.Cd-13-0286 |
0.42 |
|
| 2014 |
Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, ... Goga A, et al. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology (Baltimore, Md.). 59: 202-15. PMID 23913442 DOI: 10.1002/Hep.26662 |
0.68 |
|
| 2014 |
Kelley RK, Chang AN, Anguiano E, Hwang J, Stoppler HJ, McWhirter RM, Parks AL, Hameed B, Fix OK, Wayne EM, Nimeiri HS, Munster PN, Venook AP, Goga A. Next-generation sequencing (NGS) of serum microRNA in hepatocellular carcinoma (HCC) patients treated with sorafenib and an mTOR inhibitor. Journal of Clinical Oncology. 32: LBA204-LBA204. DOI: 10.1200/Jco.2014.32.3_Suppl.Lba204 |
0.306 |
|
| 2014 |
Kelley RK, Chang AN, Anguiano E, Hwang J, Stoppler HJ, McWhirter RM, Parks AL, Hameed B, Fix OK, Wayne EM, Nimeiri HS, Munster PN, Venook AP, Goga A. Next-generation sequencing of serum microRNA (miRNA) in hepatocellular carcinoma (HCC) patients on targeted therapy. Journal of Clinical Oncology. 32: 4096-4096. DOI: 10.1200/Jco.2014.32.15_Suppl.4096 |
0.313 |
|
| 2014 |
Horiuchi D, Zhou AY, Corella AN, Yau C, Lawson DA, Bazarov AV, Yaswen P, McManus MT, Werb Z, Welm AL, Goga A. Abstract LB-122: PIM1 kinase inhibition halts the growth of MYC-overexpressing triple-negative breast tumors Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-122 |
0.502 |
|
| 2014 |
Rohrberg J, Corella A, Starnes L, Goga A. 367: Elucidating the synthetic lethal effect of CDK inhibition in triple negative breast cancer European Journal of Cancer. 50: S88. DOI: 10.1016/S0959-8049(14)50327-9 |
0.38 |
|
| 2013 |
Olive V, Sabio E, Bennett MJ, De Jong CS, Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A, Foth M, Luftig MA, Goga A, Speed TP, Xuan Z, et al. A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife. 2: e00822. PMID 24137534 DOI: 10.7554/Elife.00822 |
0.327 |
|
| 2013 |
Olive V, Sabio E, Bennett MJ, Jong CSD, Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A, Foth M, Luftig MA, Goga A, Speed TP, Xuan Z, et al. Author response: A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis Elife. DOI: 10.7554/Elife.00822.017 |
0.305 |
|
| 2013 |
Horiuchi D, Zhou AY, Corella AN, Yau C, Lawson DA, Bazarov AV, Yaswen P, McManus MT, Welm AL, Werb Z, Goga A. Abstract B232: PIM1 kinase is essential for the growth of MYC-overexpressing triple-negative breast tumors and is an efficacious therapeutic target. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B232 |
0.482 |
|
| 2013 |
Goga A, Martins M, Corella A, Horiuchi D, Samson S, Bandyophadyay S. Abstract P5-10-01: A systems approach to combine genomics and emerging therapeutics to discover new treatments for TNBC Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-10-01 |
0.425 |
|
| 2012 |
Upton JP, Wang L, Han D, Wang ES, Huskey NE, Lim L, Truitt M, McManus MT, Ruggero D, Goga A, Papa FR, Oakes SA. IRE1α cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. Science (New York, N.Y.). 338: 818-22. PMID 23042294 DOI: 10.1126/Science.1226191 |
0.656 |
|
| 2012 |
Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. The Biochemical Journal. 447: 417-25. PMID 22853430 DOI: 10.1042/Bj20120724 |
0.666 |
|
| 2012 |
Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proceedings of the National Academy of Sciences of the United States of America. 109: 12722-7. PMID 22802621 DOI: 10.1073/Pnas.1202492109 |
0.335 |
|
| 2012 |
Horiuchi D, Huskey NE, Kusdra L, Wohlbold L, Merrick KA, Zhang C, Creasman KJ, Shokat KM, Fisher RP, Goga A. Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proceedings of the National Academy of Sciences of the United States of America. 109: E1019-27. PMID 22474407 DOI: 10.1073/Pnas.1111317109 |
0.414 |
|
| 2012 |
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. The Journal of Experimental Medicine. 209: 679-96. PMID 22430491 DOI: 10.1084/Jem.20111512 |
0.47 |
|
| 2012 |
von Morze C, Larson PE, Hu S, Yoshihara HA, Bok RA, Goga A, Ardenkjaer-Larsen JH, Vigneron DB. Investigating tumor perfusion and metabolism using multiple hyperpolarized (13)C compounds: HP001, pyruvate and urea. Magnetic Resonance Imaging. 30: 305-11. PMID 22169407 DOI: 10.1016/J.Mri.2011.09.026 |
0.307 |
|
| 2012 |
Goga A, Samson S, Horiuchi D. Abstract S3-8: Identification of Novel Synthetic-Lethal Targets for MYC-Driven Triple-Negative Breast Cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S3-8 |
0.382 |
|
| 2011 |
Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, Nelson SJ, Kurhanewicz J, Vigneron DB, Goga A. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metabolism. 14: 131-42. PMID 21723511 DOI: 10.1016/J.Cmet.2011.04.012 |
0.408 |
|
| 2011 |
Merrick KA, Wohlbold L, Zhang C, Allen JJ, Horiuchi D, Huskey NE, Goga A, Shokat KM, Fisher RP. Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Molecular Cell. 42: 624-36. PMID 21658603 DOI: 10.1016/J.Molcel.2011.03.031 |
0.342 |
|
| 2011 |
von Morze C, Larson PE, Hu S, Keshari K, Wilson DM, Ardenkjaer-Larsen JH, Goga A, Bok R, Kurhanewicz J, Vigneron DB. Imaging of blood flow using hyperpolarized [(13)C]urea in preclinical cancer models. Journal of Magnetic Resonance Imaging : Jmri. 33: 692-7. PMID 21563254 DOI: 10.1002/Jmri.22484 |
0.313 |
|
| 2011 |
Chow EK, Zhang XQ, Chen M, Lam R, Robinson E, Huang H, Schaffer D, Osawa E, Goga A, Ho D. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Science Translational Medicine. 3: 73ra21. PMID 21389265 DOI: 10.1126/Scitranslmed.3001713 |
0.389 |
|
| 2011 |
Marcusson EG, Balakrishnan A, Chang AN, Bhat B, Goga A. Abstract 4708: Preclinical development of an anti-miR-21 compound for hepatocellular carcinoma Cancer Research. 71: 4708-4708. DOI: 10.1158/1538-7445.Am2011-4708 |
0.374 |
|
| 2010 |
Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, ... ... Goga A, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nature Medicine. 16: 1134-40. PMID 20871609 DOI: 10.1038/Nm.2227 |
0.688 |
|
| 2010 |
Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proceedings of the National Academy of Sciences of the United States of America. 107: 13836-41. PMID 20643922 DOI: 10.1073/Pnas.1008366107 |
0.411 |
|
| 2010 |
den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 116: 1498-505. PMID 20519624 DOI: 10.1182/Blood-2009-11-251074 |
0.366 |
|
| 2010 |
Greenberg S, Park JW, Melisko ME, Goga A, Moasser MM, Anderson M, Scott JH, Petrillo LA, Moore DH, Rugo HS. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results. Journal of Clinical Oncology. 28: 1002-1002. DOI: 10.1200/Jco.2010.28.15_Suppl.1002 |
0.345 |
|
| 2010 |
Chien AJ, Aicardi J, Melisko ME, Goga A, Moasser MM, Park JW, Munster PN, Rugo HS. Phase I/II study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology. 28: 1067-1067. DOI: 10.1200/Jco.2008.26.15_Suppl.13540 |
0.327 |
|
| 2010 |
Balakrishnan A, Lim L, Cairo S, Chandriani S, Jones KD, Buendia M, Goga A. Abstract B54: Molecular basis of oncogene cooperation in liver cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B54 |
0.707 |
|
| 2010 |
Goga A, Horiuchi D, Kusdra L, Chandriani S, Lenburg M, Gonzalez-Angulo A, Huskey N, Creasman K, Davis S, Mills G, Esserman L. Abstract S5-4: Synthetic-Lethality of Triple-Negative Breast Cancers Via the MYC Oncogene Pathway Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-S5-4 |
0.476 |
|
| 2009 |
Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, McManus MT. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. The Journal of Biological Chemistry. 284: 18515-24. PMID 19419954 DOI: 10.1074/Jbc.M109.006676 |
0.461 |
|
| 2009 |
Lyandres J, Melisko M, Moasser M, Goga A, Park J, Rugo H. Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer. Cancer Research. 69: 4119. DOI: 10.1158/0008-5472.Sabcs-4119 |
0.32 |
|
| 2009 |
Johnstone C, Lucas E, Kusdra L, Goga A, Anderson R. The Role of microRNA Genes in Breast Cancer Progression and Metastasis. Cancer Research. 69: 6142-6142. DOI: 10.1158/0008-5472.Sabcs-09-6142 |
0.396 |
|
| 2009 |
Huskey NE, Horiuchi D, Kusdra L, Zhang C, Shokat K, Goga A. Abstract C68: Using a chemical genetic approach to define the role of CDK2 in normal and transformed cell lines Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C68 |
0.4 |
|
| 2009 |
Horiuchi D, Kusdra L, Klein‐McDowell M, Creasman KJ, Goga A. Abstract C23: Therapy of triple‐negative breast tumors by targeting the MYC oncogene pathway Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C23 |
0.492 |
|
| 2008 |
Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, Moore DH, Rugo HS. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 559. PMID 27948442 DOI: 10.1200/Jco.2008.26.15_Suppl.559 |
0.367 |
|
| 2008 |
Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, Pontoglio M, Strick-Marchand H, Levillayer F, Nouet Y, Rickman D, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 14: 471-84. PMID 19061838 DOI: 10.1016/J.Ccr.2008.11.002 |
0.407 |
|
| 2007 |
Goga A, Benz C. Anti-oncomir suppression of tumor phenotypes. Molecular Interventions. 7: 199-202, 180. PMID 17827440 DOI: 10.1124/Mi.7.4.6 |
0.364 |
|
| 2007 |
Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nature Medicine. 13: 820-7. PMID 17589519 DOI: 10.1038/Nm1606 |
0.415 |
|
| 2007 |
Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. The Journal of Biological Chemistry. 282: 1479-86. PMID 17110380 DOI: 10.1074/Jbc.M609383200 |
0.362 |
|
| 1997 |
Moro M, Walkenhorst J, Goga A, Witte ON, Superti-Furga G. A functional screen for regulators of the c-Abl protein tyrosine kinase Leukemia. 11: 313-315. PMID 9209375 DOI: 10.1038/Sj.Leu.2400616 |
0.33 |
|
| 1995 |
Goga A, McLaughlin J, Afar DEH, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene Cell. 82: 981-988. PMID 7553858 DOI: 10.1016/0092-8674(95)90277-5 |
0.317 |
|
| 1994 |
Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc Science. 264: 424-426. PMID 8153630 DOI: 10.1126/Science.8153630 |
0.305 |
|
| 1994 |
Cohen L, Mohr R, Chen YY, Huang M, Kato R, Dorin D, Tamanoi F, Goga A, Afar D, Rosenberg N. Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America. 91: 12448-52. PMID 7809057 DOI: 10.1073/Pnas.91.26.12448 |
0.333 |
|
| 1993 |
Goga A, McLaughlin J, Pendergast AM, Parmar K, Muller A, Rosenberg N, Witte ON. Oncogenic activation of c-ABL by mutation within its last exon. Molecular and Cellular Biology. 13: 4967-75. PMID 8336729 DOI: 10.1128/Mcb.13.8.4967 |
0.303 |
|
| Show low-probability matches. |